Patents by Inventor Jon H. Come

Jon H. Come has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11866446
    Abstract: The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: January 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jun Myun Ahn, Samantha Angle, Michael Aaron Brodney, Jingrong Cao, John E. Cochran, Jon H. Come, Leslie A. Dakin, Elena Dolgikh, Brad D. Maxwell, Suganthini S. Nanthakumar, Hardwin O'Dowd, Jessica Howard Olsen, Timothy J. Senter, Akira Joseph Shimizu, Steven David Stone, Haoxuan Wang
  • Publication number: 20230271945
    Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
    Type: Application
    Filed: February 7, 2023
    Publication date: August 31, 2023
    Inventors: Jingrong CAO, Jon H. COME, Leslie A. DAKIN, Francois DENIS, Warren A. DORSCH, Anne FORTIER, Martine HAMEL, Elaine B. KRUEGER, Brian LEDFORD, Suganthini S. NANTHAKUMAR, Olivier NICOLAS, Camil SAYEGH, Timothy J. SENTER, Tiansheng WANG, Michael BRODNEY, Kan-Nian HU, Peter ROSE, Kevin GAGNON, Yi SHI, Muna SHRESTHA, Ales MEDEK, Faith WITKOS
  • Patent number: 11618746
    Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: April 4, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jingrong Cao, Jon H. Come, Leslie A. Dakin, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Suganthini S. Nanthakumar, Olivier Nicolas, Camil Sayegh, Timothy J. Senter, Tiansheng Wang, Michael Brodney, Kan-Nian Hu, Peter Rose, Kevin Gagnon, Yi Shi, Muna Shrestha, Ales Medek, Faith Witkos
  • Publication number: 20230014907
    Abstract: The disclosure provides compounds of Formula I, deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.
    Type: Application
    Filed: June 11, 2021
    Publication date: January 19, 2023
    Inventors: Leslie A. Dakin, Timothy J. Senter, Jingrong Cao, Jon H. Come, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Francois Maltais, Suganthini S. Nanthakumar, Olivier Nicolas, Camil E. Sayegh, Tiansheng Wang
  • Publication number: 20230011118
    Abstract: The disclosure provides at least one compound, reiterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), reiterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.
    Type: Application
    Filed: June 11, 2021
    Publication date: January 12, 2023
    Inventors: Leslie A. Dakin, Timothy J. Senter, Jingrong Cao, Jon H. Come, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Francois Maltais, Suganthini S. Nanthakumar, Olivier Nicolas, Camil E. Sayegh, Tiansheng Wang
  • Publication number: 20220340523
    Abstract: The disclosure provides at least one entity chosen from compounds of Formula (I) pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.
    Type: Application
    Filed: January 28, 2021
    Publication date: October 27, 2022
    Inventors: Leslie A. DAKIN, Timothy J. SENTER, Jingrong CAO, Jon H. COME, Francois DENIS, Warren A. DORSCH, Anne FORTIER, Martine HAMEL, Elaine B. KRUEGER, Brian LEDFORD, Francois MALTAIS, Suganthini S. NANTHAKUMAR, Olivier NICOLAS, Camil E. SAYEGH, Tiansheng WANG
  • Publication number: 20220106327
    Abstract: The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
    Type: Application
    Filed: August 26, 2021
    Publication date: April 7, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Jun Myun AHN, Samantha ANGLE, Michael Aaron BRODNEY, Jingrong CAO, John E. COCHRAN, Jon H. COME, Leslie A. DAKIN, Elena DOLGIKH, Brad D. MAXWELL, Suganthini S. NANTHAKUMAR, Hardwin O'DOWD, Jessica Howard OLSEN, Timothy J. SENTER, Akira Joseph SHIMIZU, Steven David STONE, Haoxuan WANG
  • Publication number: 20200377479
    Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomeulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
    Type: Application
    Filed: December 17, 2019
    Publication date: December 3, 2020
    Inventors: Jingrong CAO, Jon H. COME, Leslie A. DAKIN, Francois DENIS, Warren A. DORSCH, Anne FORTIER, Martine HAMEL, Elaine B. KRUEGER, Brian LEDFORD, Suganthini S. NANTHAKUMAR, Olivier NICOLAS, Camil SAYEGH, Timothy J. SENTER, Tiansheng WANG, Michael BRODNEY, Kan-Nian HU, Peter Rose, Kevin GAGNON, Yi SHI, Muna SHRESTHA, Ales MEDEK, Faith WITKOS
  • Patent number: 10183933
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: January 22, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Anne-Laure Grillot, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Jingrong Cao, Upul Keerthi Bandarage, Suganthini S. Nanthakumar
  • Publication number: 20180251431
    Abstract: Disclosed are chemical entities which are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Formula (I) has the structure, R1a, R1b, R2, R3, R4a, R4b and Y are as defined herein. These chemical entities are useful for reduction of very long chain fatty acid levels. These chemical entities and pharmaceutically acceptable compositions comprising such chemical entities can be useful for treating various diseases, disorders and conditions, such as adrenoleukodystrophy (ALD).
    Type: Application
    Filed: December 8, 2017
    Publication date: September 6, 2018
    Inventors: Paul S. Charifson, Jon H. Come, John J. Court, Zachary Gale-Day, Wenxin Gu, Katrina L. Jackson, Sanjay Shivayogi Magavi, Suganthini S. Nanthakumar, Steven Michael Ronkin, Rebecca Jane Swett, Qing Tang
  • Publication number: 20170260175
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 14, 2017
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Anne-Laure Grillot, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Jingrong Cao, Upul Keerthi Bandarage, Suganthini S. Nanthakumar
  • Patent number: 9676759
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: June 13, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Anne-Laure Grillot, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Jingrong Cao, Upul Keerthi Bandarage, Suganthini S. Nanthakumar
  • Publication number: 20140038936
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: May 7, 2013
    Publication date: February 6, 2014
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Anne-Laure Grillot, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Jingrong Cao, Upul Keerthi Bandarage, Suganthini S. Nanthakumar
  • Patent number: 8466288
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: June 18, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, Jr., Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Suganthini S. Nanthakumar, Jingrong Cao, Upul Keerthi Bandarage, Anne-Laure Grillot
  • Patent number: 8344153
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: January 1, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin Michael Cottrell, Alex Aronov, Robert J. Davies, Jon H. Come, David Messersmith, Jinwang Xu, Upul Keerthi Bandarage, Jingrong Cao
  • Patent number: 8278306
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: October 2, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Jingrong Cao, Upul Keerthi Bandarage, Jon H. Come, Craig Marhefka
  • Patent number: 8268999
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: September 18, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, Jon H. Come, Kevin Michael Cottrell, Arnaud Le Tiran, Valerie Marone, Gabriel Martinez Botella, David Messersmith, Emilie Porter Huck, Ronald Lee Grey, Jr.
  • Publication number: 20120202784
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: January 13, 2012
    Publication date: August 9, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, JR., Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Suganthini S. Nanthakumar, Jingrong Cao, Upul Keerthi Bandarage, Anne-Laure Grillot
  • Publication number: 20120053187
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: August 24, 2011
    Publication date: March 1, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Alex Aronov, Jon H. Come, Kevin Michael Cottrell, Arnaud Le Tiran, Valerie Marone, Gabriel Martinez Botella, David Messersmith, Emilie Porter Huck, Ronald Lee Grey, JR.
  • Publication number: 20120040950
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: December 21, 2010
    Publication date: February 16, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, JR., Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Suganthini S. Nanthakumar, Jingrong Cao, Upul Keerthi Bandarage, Anne-Laure Grillot